Quality Of Life Data Excluded From Tarceva Label Due To Lack Of Validation
This article was originally published in Pharmaceutical Approvals Monthly
Tarceva labeling excludes quality of life claims sought by Genentech/OSI in part because patient questionnaire components were not validated for stand-alone use, FDA review documents show
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class